Cancer prevention through metabolic remission

Nat Rev Endocrinol. 2026 Jun 2. doi: 10.1038/s41574-026-01268-3. Online ahead of print.

Andreas L Birkenfeld^{1

2

3

4}, Mathias Heikenwälder^{5

6

7

8}

¹ Institute for Diabetes Research and Metabolic Diseases, Helmholtz Diabetes Center, Helmholtz Munich, Munich, Germany. andreas.birkenfeld@med.uni-tuebingen.de.
² German Center for Diabetes Research (DZD), Neuherberg, Germany. andreas.birkenfeld@med.uni-tuebingen.de.
³ Internal Medicine IV, Department of Diabetology, Endocrinology and Nephrology, University of Tübingen, Tübingen, Germany. andreas.birkenfeld@med.uni-tuebingen.de.
⁴ Diabetes and Obesity Theme, School of Cardiovascular and Metabolic Medicine and Sciences, Faculty of Life Sciences and Medicine, Kings College London, London, UK. andreas.birkenfeld@med.uni-tuebingen.de.
⁵ Division of Chronic Inflammation and Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany.
⁶ Cluster of Excellence iFIT (EXC 2180) 'Image-Guided and Functionally Instructed Tumor Therapies', University of Tübingen, Tübingen, Germany.
⁷ M3-Research Center for Malignome, Metabolome and Microbiome, Institute for Interdisciplinary Research on Cancer Metabolism and Chronic Inflammation, Faculty of Medicine, University of Tübingen, Tübingen, Germany.
⁸ Cluster of Excellence EXC 2124 Controlling Microbes to Fight Infections, University of Tübingen, Tübingen, Germany.

No abstract available